In lung cancer, METTL14 stabilizes HSD17B6 mRNA through m6A modification, suppressing CD8+ T-cell infiltration and activation, ultimately facilitating tumor progression and impairing PD-1 blockade efficacy (Figure 2) (13). Here, METTL14 is linked to lung carcinoma.